Alerts to physician NP electronic prescription discontinuation represented 9.8% of PI. In 2016–2017, the waste in supplemented bags with expired date resulted in a loss of € 526/year on average. The reason for this waste was verbal NP discontinuation. These alerts, together with a better communication with nursing teams, resulted in zero waste. Other PI were: electrolytic imbalances corrections (5.4%), scheduling of NP suspension days (4.3%), hydric imbalances adjustments (2.2%) and correction of prescribed lipid supplements (2.2%). All standard bags were supplemented in a laminar flow chamber. Only one patient presented central venous catheter (CVC) infection with positive blood culture. In the homologous period of 2013–2014, when the bags were supplemented in the wards, the number of CVC infections was six.

Conclusion Pharmacists are key elements with a recognised value of their interventions (90.2% acceptance rate) which improved the adequacy and safety of PN concerning metabolic- and catheter-related complications.

REFERENCE AND/OR ACKNOWLEDGEMENTS

Giancarelli A, Davanos E. Evaluation of nutrition support pharmacist interventions. *JPEN* 2014;39:476–81. Available from <https://www.ncbi.nlm.nih.gov/pubmed/25303948>

No conflict of interest.

4CPS-207 SCREENING FOR PAINFUL DIABETIC NEUROPATHY

¹R Bs*, ¹H Ghada, ¹S Yasmine, ¹K Mohamed Amine, ²D Mehdi, ¹Y Mohamed Ali. ¹Military Hospital Hmpit Tunis, Internal Pharmacy, Tunis, Tunisia; ²Faculty of Pharmacy, Department of Pharmacology, Monastir, Tunisia

10.1136/ejhp-2019-eahpconf.356

Background Neurological complications are common in diabetes and mainly result in peripheral neuropathy.

Purpose The aim of this study was to detect PDN in a diabetic population and describe the factors associated with this complication.

Material and methods This is a descriptive and analytical study of a total of 90 diabetic patients who were hospitalised or consulted between June and August 2018 in the endocrinology department of our hospital. For screening we used the DN4 questionnaire. This questionnaire is divided into four questions representing 10 items to check. For each patient we counted a score. If the score was greater than or equal to 4/10, the test was positive. For patient information we used a pre-established record card.

Results The study population had a mean age of 54.3 ± 15.35 years, a sex ratio (M/F) of 0.84 and was predominantly composed of type-2 diabetics (88%). Thirty patients screened positive on the DN4 ($\geq 4/10$). PDN was not associated with age ($p=0.412$), sex ($p=0.549$) or type of diabetes ($p=0.111$). It was associated with high blood pressure ($p=0.007$), insulin ($p=0.003$) and metformin ($p=0.022$).

Conclusion The DN4 questionnaire is a simple tool that facilitates the recognition of painful diabetic neuropathy, which is a frequent and sometimes disabling complication of diabetes.

REFERENCES AND/OR ACKNOWLEDGEMENTS

http://www.eahp.eu/sites/default/files/files/ejhp-2013-000276_Single_PDF.pdf

No conflict of interest.

4CPS-208 CHOOSING THE RIGHT WOUND DRESSING FOR THE RIGHT PRESSURE ULCER: THE DEVELOPMENT OF A COLOUR-BASED CHART HELPING HEALTHCARE PROVIDERS

E Calzavara*, L Gambitta, E Galfrascoli, P Richelmi, MLA Medaglia. *ASST Fatebenefratelli-Sacco- P.O. Fatebenefratelli e oftalmico, Pharmacy Unit, Milan, Italy*

10.1136/ejhp-2019-eahpconf.357

Background Pressure ulcers (PUs) are a complex problem that affects many patients in every hospital ward. The main goal of healthcare providers is to treat patients' major diseases, leading often to an underestimation of PUs. Thanks to a multidisciplinary group led by a hospital pharmacist, every year a course is organised to train nurses in recognising and managing PUs, and to improve the appropriate use of wound dressings. Over the years, many types of wound dressings have been developed and are now available: they differ in material, technology and use. Healthcare providers could be given a tool helping them choose among the different products available.

Purpose The objective was to develop a tool that could help nurses in choosing the right dressing for the right PU, leading to a better treatment of PUs.

Material and methods We collected all the wound dressings available in our hospital and identified, for each dressing, destination of use and mechanism of action. We set up an easy chart characterised by a colour-code that identified the different stages of a PU and for each stage we selected the most suitable dressing. Starting from the internal procedure PRAO85 and thanks to the collaboration of the whole group, a schematic diagram was developed, to facilitate the decision-making process.

Results A total of 22 different kinds of wound dressings are available in our hospital: we set up a colour-based diagram that collects all the dressings. It is based on four colours, representing the principal kinds of lesions:

- Yellow (slough, fibrine);
- Red (granulation tissue);
- Green (infected lesion);
- Black (necrotic tissue).

Each wound dressing used in our hospital was then associated with one of the previous colours, lesions' staging and medications to be used in conjunction with. All this information is represented in a pivot table. The diagram was printed as a poster to be easily available to healthcare providers during wound rounds.

Conclusion Thanks to our multidisciplinary group, the awareness of all healthcare providers is growing. The ongoing collaboration is providing fundamental tools to improve the quality of wound care. A colour-code system can improve the appropriate use of dressings. Continuous collaboration allows hospital-based standardised criteria to prevent and treat PUs.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

4CPS-209 OUTCOMES RESEARCH ON NEW TYROSINE KINASE INHIBITORS FOR NON-SMALL CELL LUNG CANCER

¹P Cardoso*, ¹M Capoulas, ¹T Lobo, ²C Matos, ²M Felizardo, ¹R Oliveira, ¹C Santos. ¹Hospital Beatriz Ângelo, Hospital Pharmacy, Loures, Portugal; ²Hospital Beatriz Ângelo, Pneumology, Loures, Portugal

10.1136/ejhp-2019-eahpconf.358

Background Information technologies' development and their integration in healthcare processes brought a major role in data generation to the pharmacy department. This massive data, also known as BIG DATA, is a powerful resource to initiate the measurement of healthcare outcomes related to dispensed drugs.

Purpose To access the main health outcomes of patients who received new tyrosine kinase inhibitors (TKI) and to develop a tool which provides real-life information based on the hospital environment to support the clinical decision.

Material and methods Every patient's data was collected from the electronic medical records, from 2013 until 2017. For each patient, we recorded the outcome, the performance status and the duration of the treatment. The main analysis outcome was the overall survival (OS). The survival analysis was done using IBM SPSS Statistics.

Results Of the estimated glomerular filtration rate +patients, the majority received Erlotinib (n=42), either as second/third lines (n=30) or first line (n=12). The number of patients who took Gefitinib was smaller than Erlotinib (n=4). All the ALK +patients were treated with Crizotinib (n=5).

The observed median survival was 20.3 months for TKI in the line (n=21) and 3.2 months for the second/third lines (n=30), with $p < 0.0001$. The median OS for Erlotinib in the first line was 21.3 months and 2.8 months for patients in the second/third lines. For Crizotinib, the observed median OS was 13.8 months, with an 18 month follow up. The sample was too small for the Gefitinib survival analysis.

Conclusion There is a major difference in the OS of TKIs used in the first versus second and further lines, which was expected since these patients present a higher ECOG PS than the first-line group. This study shows that the real-world data, even with small samples in single-centre studies, can be similar to clinical trials data, as our OS with Erlotinib is nearly identical to the one reported in the OPTIMAL study.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1. Stokes LB, Rogers JW, Hertig JB, Weber RJ. *Big data: implications for health system pharmacy.* *Hosp Pharm* 2016;51:599–603.
2. Nan X, Xie C, Yu X, Liu J. *EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.* *Oncotarget* 2017;8:75712–26.

No conflict of interest.

4CPS-210 PATIENTS IN CLINICAL TRIALS AND THEIR TREATMENT: DID THE PRESCRIPTION SUPPORT A FIRST-LINE INFORMATION TOOL?

A Carmona*, A Cransac, J Paris, C Brun, L Porcher, M Boulin, C Pemot. *CHU Francois Mitterrand, Pharmacy, Dijon, France*

10.1136/ejhp-2019-eahpconf.359

Background According to the Code of Public Health, the pharmacist advises and informs the patient to ensure the right use and high drug adherence. In clinical trials (CT), investigational medicinal products (IMP) are dispensed by the pharmacy department. A copy of the prescription is given to the patients in ambulatory: it is a support to information for the patient available at any time at home. In our hospital, prescriptions for CT are usually provided by the sponsor.

Purpose The purpose of this work was to evaluate information about IMP on the prescriptions provided by the sponsors and to propose areas for improvement.

Material and methods All the CTs with at least one IMP was taken at home and opened in the pharmacy department of a university hospital on 1 January 2018 were included in this retrospective study. A checklist of eight criteria deemed essential to inform the patient regarding his treatment was created in accordance with the regulations.

Results A total of 93 CTs were evaluated, 35% were institutional CTs. Eleven per cent (n=10) of the prescriptions contained none of the listed criteria. For each criterion, the proportion of prescriptions including the information was 83% for dosage, 69% for product's conditioning, 43% for treatment's duration, 25% for time of taking, 19% for intake, 5% for storage temperature, 2% for adverse reactions and 0% for drug interactions. Eighty-eight per cent (n=82) of the evaluated CTs were oral IMP and 30% (n=25) were chemotherapies.

Conclusion The most frequent information on prescriptions is the dosage and the packaging of the IMP. At the other end, information on what to do in case of adverse events and drug interactions are rare or non-existent. The pharmacist has an important and essential role in dispensing pharmaceutical advice for CT.¹ A collaboration between services and pharmacy is planned in order to establish a standard prescription for CTs with specific information. Improving the quality of prescription information will optimise the safety of IMP taking.

REFERENCE AND/OR ACKNOWLEDGEMENTS

1. Schoenenberger JA, et al. Assessment of the information on investigational oral treatment provided to patients in clinical trials. *Euro J Hosp Pharm* 2012; (19):230–1.

No conflict of interest.

4CPS-211 IMPACT OF THE ELECTRONIC PRESCRIPTION IN AN EMERGENCY DEPARTMENT

C Casanova Martínez*, A Pérez-Landeiro, L Otero Millán, L Pérez Rodríguez, K Lorenzo Lorenzo, B Leboreiro Enríquez, G Piñero Corrales. *Hospital Álvaro Cunqueiro, Servicio Farmacia, Vigo, Spain*

10.1136/ejhp-2019-eahpconf.360

Background The emergency medicine (EM) pharmacist, on working days, performs medication review and reconciliation. The EM pharmacist communicates, verbally or through small reports, the interventions to the doctor. After the electronic prescription (EP) implementation, in October 2017, these reports changed to a messaging system of the prescription programme.

Purpose To analyse the impact of the EP on EM pharmacist interventions.

Material and methods Unicentric, observational and prospective study conducted in a tertiary university hospital. We included all patients in the emergency department observation area (30 beds). The interventions reported in the first semester of 2017 (pre-intervention) were compared with the first semester of 2018 (post-intervention).

The results of this activity were collected in a spreadsheet (Excel). We recorded the intervention type and its acceptance. **Results** In 2017, 1178 patients had at least one intervention on their medication (29.7% of the total) and we performed 1605 pharmaceutical interventions (1.4 intervention/patient). In 2018, 491 patients (12.4% of the total) and 744 interventions (1.5 intervention/patient).